At a glance
ClinicalIndex Comparison RecordN/ACompleted· 320 enrolled
Drug / intervention
OneTouch® Ultra®2 System +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Benefits of a Blood Glucose Monitoring System in Patients With Type 2 Diabetes
In Brief
A clinical study evaluating OneTouch® Ultra®2 System and Standard care for Diabetes Mellitus, Type 2. Completed, enrolled 320 participants across 18 sites in 3 countries.
Detailed Summary
Clinical benefits of the OneTouch® Ultra®2 BGMS versus standard BGMS during 52 weeks of use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesCanada, United Kingdom, United States
CollaboratorsSynexus(UK), CPS(UK), Battelle CRO(US), RPS CRO(US), Robertson Centre For Biostatistics (UK)
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedNov 2006
Primary CompletionJan 2009
TodayJul 2026
First PostedNov 20, 2006
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.6 years ago
Interventions
OneTouch® Ultra®2 Systembehavioral
Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
Standard carebehavioral
Standard education and self-monitoring of blood glucose performed with traditional meter systems